Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma (NCT00041210) | Clinical Trial Compass
UnknownPhase 3
Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma
United Kingdom850 participantsStarted 2001-10
Plain-language summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients who have advanced Hodgkin's lymphoma.
PURPOSE: Randomized phase III trial to compare the effectiveness of two different combination chemotherapy regimens in treating patients who have advanced Hodgkin's lymphoma.
Who can participate
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed Hodgkin's lymphoma (any sub-type)
* Stage IB, IIB, IIIA, IIIB, or IV OR
* Stage IA or IIA with locally extensive disease (e.g., bulky mediastinal disease (e.g., greater than 0.33 of the maximum transthoracic diameter on routine chest X-ray or at least 2 extranodal sites of disease))
PATIENT CHARACTERISTICS:
Age:
* 18 to 60
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Complete blood count normal unless directly due to Hodgkin's lymphoma
Hepatic:
* Hepatic function normal unless directly due to Hodgkin's lymphoma
Renal:
* Renal function normal unless directly due to Hodgkin's lymphoma
Cardiovascular:
* No pre-existing cardiac disease
Pulmonary:
* No pre-existing pulmonary disease
Other:
* Not pregnant
* Fertile patients must use effective contraception during and for six months after study
* HIV negative
* No other prior malignancy except basal cell or squamous cell skin cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* Not specified
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* Not specified
Other:
* No prior therapy for Hodgkin's lymphoma
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Relapse-free survival
Trial details
NCT IDNCT00041210
SponsorMount Vernon Cancer Centre at Mount Vernon Hospital